Abstract
Carbonic anhydrases (EC 4.2.1.1) are ubiquitous metalloenzymes present in prokaryotes and eukaryotes that are encoded by five evolutionarily unrelated gene families involved in numerous physiological and pathological processes. Novel interesting chemo types, in addition to the sulfonamide and sulfamate were discovered, many of which are based on natural products, such as phenols/polyphenols, phenolic acids, and coumarins. Methanolic extract of Abrus precatorius belongs to family Fabaceae tested for human carbonic anhydrase (hCA) I and II inhibition study. The significant IC 50 values are calculated for the methanolic extract of Abrus precatorius for hCA I found to be 0.13 mM/ml which is showing relatively less potent inhibition than hCA against hCA II having IC 50 values of 0.12 mM/ml. Abrus precatorius is a weak inhibitor that may constitute leads for developing tighter binding compounds.
Keywords: Carbonic anhydrase, carbonic enzyme inhibitor, natural product, Abrus precatorius, phenolic compounds, metalloenzymes, calcification, tumorigenicity, edema, glaucoma
Current Enzyme Inhibition
Title: Carbonic Anhydrase I and II Inhibition with Natural Products: Abrus precatorius
Volume: 7 Issue: 2
Author(s): Kalyan K. Sethi, Padilam Suresh and Sumanta Mondal
Affiliation:
Keywords: Carbonic anhydrase, carbonic enzyme inhibitor, natural product, Abrus precatorius, phenolic compounds, metalloenzymes, calcification, tumorigenicity, edema, glaucoma
Abstract: Carbonic anhydrases (EC 4.2.1.1) are ubiquitous metalloenzymes present in prokaryotes and eukaryotes that are encoded by five evolutionarily unrelated gene families involved in numerous physiological and pathological processes. Novel interesting chemo types, in addition to the sulfonamide and sulfamate were discovered, many of which are based on natural products, such as phenols/polyphenols, phenolic acids, and coumarins. Methanolic extract of Abrus precatorius belongs to family Fabaceae tested for human carbonic anhydrase (hCA) I and II inhibition study. The significant IC 50 values are calculated for the methanolic extract of Abrus precatorius for hCA I found to be 0.13 mM/ml which is showing relatively less potent inhibition than hCA against hCA II having IC 50 values of 0.12 mM/ml. Abrus precatorius is a weak inhibitor that may constitute leads for developing tighter binding compounds.
Export Options
About this article
Cite this article as:
K. Sethi Kalyan, Suresh Padilam and Mondal Sumanta, Carbonic Anhydrase I and II Inhibition with Natural Products: Abrus precatorius, Current Enzyme Inhibition 2011; 7 (2) . https://dx.doi.org/10.2174/157340811796575272
DOI https://dx.doi.org/10.2174/157340811796575272 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Commentary: Participation of Sox-1 Expression and Signaling of β-Catenin in the Pathophysiology of Generalized Seizures in Cerebellum of Rat
CNS & Neurological Disorders - Drug Targets Gene Transfer for Inborn Errors of Metabolism of the Liver: The Clinical Perspective
Current Pharmaceutical Design Evaluation of Anticonvulsant Activity and Toxicity Screening of Semicarbazones Derived from Quinazolinone Scaffold
Current Bioactive Compounds Anxiolytic-Like Effects of 7H-Benzo[e]perimidin-7-One Derivatives through Elevated Plus-Maze Test in Mice
Current Topics in Medicinal Chemistry Editorial
Drug Delivery Letters Therapeutic Targeting of Epigenetic Components in Amyotrophic Lateral Sclerosis (ALS)
Current Medicinal Chemistry BACE1 Levels Correlate with Phospho-Tau Levels in Human Cerebrospinal Fluid
Current Alzheimer Research Pycnogenol Protects against Pentylenetetrazole-Induced Oxidative Stress and Seizures in Mice
Current Clinical Pharmacology A2A Adenosine Receptor and its Modulators: Overview on a Druggable GPCR and on Structure-Activity Relationship Analysis and Binding Requirements of Agonists and Antagonists
Current Pharmaceutical Design Drug-Resistance in Central Nervous System Tumors: From the Traditional Cell-Resistance Model to the Genetically Driven Approaches on Therapy
Current Pharmaceutical Biotechnology Adult Neurogenesis in Mesial Temporal Lobe Epilepsy: A Review of Recent Animal and Human Studies
Current Pharmaceutical Biotechnology Next Generation Sequencing in the Management of Leptomeningeal Metastases of Non-Small Cell Lung Cancer: A Case Report and Literature Review
Recent Patents on Anti-Cancer Drug Discovery Potential Therapeutic Relevance of Adenosine A2B and A2A Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic: Ion Channels: Applications in Ion Channel Drug Discovery(Guest Editor: Douglas S. Krafte)]
Combinatorial Chemistry & High Throughput Screening The Biology of the RNA Binding Protein Guanine-Rich Sequence Binding Factor 1
Current Protein & Peptide Science The Gastrin-Releasing Peptide Receptor as a Therapeutic Target in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Subject Index To Volume 6
Current Topics in Medicinal Chemistry Chvostek's Sign in Paediatric Practice
Current Pediatric Reviews Recent Updates in Imperative Natural Compounds for Healthy Brain and Nerve Function: A Systematic Review of Implications for Multiple Sclerosis
Current Drug Targets Functional Connectivity in a Rat Model of Alzheimer's Disease During a Working Memory Task
Current Alzheimer Research